Related Experiment Video
Updated: Jan 2, 2026

Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
Management of delayed encephalopathy after CO poisoning: An evidence-based narrative review
Xiao-Min Xu1, Hua Luo, Ben-Bing Rong
1Department of Neurology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Background:
Approximately 10% to 30% patients develop delayed encephalopathy after acute CO poisoning (DEACMP). No specific treatment is available and poor prognosis is a characteristic of this disease. We aimed to evaluate the efficacy and safety of all therapies that have been tried in randomized controlled trial (RCT) for DEACMP.
Methods:
We conducted a systematic search of the Cochrane, Embase, PubMed, and Web of Science databases.
Results:
Overall, 4 RCTs were identified in our study. Both hyperbaric oxygen (HBO) and mesenchymal stem cell (MSC) transplantation were effective in DEACMP, and MSC seemed to be superior to HBO. The addition of dexamethasone, N-butylphthalide, or XingZhi-YiNao granules into HBO, or butylphthalide into MSC could achieve better neurological recovery in DEACMP patients but did not significantly increase the incidence of adverse events.
Conclusion:
Several therapies have shown positive results in treating DEACMP and need to be proven by further studies.
More Related Videos
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Acute Respiratory Failure-III
Prevention of Further Absorption of Poison
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

